: A novel gene fusion in malignant melanoma
Oncogenic gene fusions have been identified in many cancers, and many serve as druggable targets for therapy. Fibroblast growth factor receptor (FGFR) gene aberration is known to be associated with tumor progression and resistance to anticancer therapy. Here we report the first case of malignant mel...
Main Authors: | Jiyun Lee, Jeeyun Lee, Sang Duk Hong, Kee-Taek Jang, Su Jin Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Sungkyunkwan University School of Medi
2018-06-01
|
Series: | Precision and Future Medicine |
Subjects: | |
Online Access: | http://www.pfmjournal.org/upload/pdf/pfm-2018-00044.pdf |
Similar Items
-
Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer
by: Youjin Kim, et al.
Published: (2017-12-01) -
FGFR3–TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle
by: Sourav Sarkar, et al.
Published: (2017-01-01) -
Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
by: Leomar Y. Ballester, et al.
Published: (2019-04-01) -
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
by: Douglas A. Mata, et al.
Published: (2020-11-01) -
Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
by: Maria-Magdalena Georgescu, et al.
Published: (2021-04-01)